


UPDATE ON LIRAGLUTIDE (SAXENDA®) FOR WEIGHT MANAGEMENT



The HSE introduced a managed access protocol (MAP) for liraglutide (Saxenda®) in January 2023. The aim of the MAP is to provide patients with an initial body mass index (BMI) greater than or equal to 35 kg/m^2 , with prediabetes and high-risk for cardiovascular disease, with access to reimbursement support for liraglutide (Saxenda®) for weight management.

Liraglutide (Saxenda®) is a glucagon-like peptide-1 analogue, and is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients.

By December 2024, over 3,700 patients were accessing treatment with liraglutide (Saxenda®) under the Community Drug Schemes. Between January 2023 and December 2024, expenditure on liraglutide (Saxenda®) under the Drugs Payment and General Medical Services schemes was €11.49 million.

February 2025

HSE Medicines Management Programme.